

# International Nonproprietary Names for Pharmaceutical Substances (INN)

---

## RECOMMENDED International Nonproprietary Names: List 60

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wild Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–96) and Recommended (1–57) International Nonproprietary Names can be found in *Cumulative List No. 12, 2007* (available in CD-ROM only).

## Dénominations communes internationales des Substances pharmaceutiques (DCI)

### Dénominations communes internationales RECOMMANDÉES: Liste 60

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–96) et recommandées (1–57) dans la *Liste récapitulative No. 12, 2007* (disponible sur CD-ROM seulement).

## Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

### Denominaciones Comunes Internacionales RECOMENDADAS: Lista 60

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–96) y Recomendadas (1–57) se encuentran reunidas en *Cumulative List No. 12, 2007* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:

Recommended INN

Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée

Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada

Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada

**adiplonum**

adiplon


7-[[2-(3-fluoropyridin-2-yl)-1H-imidazol-1-yl]methyl]-2-methyl-8-propyl[1,2,4]triazolo[1,5-c]pyrimidine

adiplon

7-[[2-(3-fluoropyridin-2-yl)-1H-imidazol-1-yl]méthyl]-2-méthyl-8-propyl[1,2,4]triazolo[1,5-c]pyrimidine

adiplón

7-[[2-(3-fluoropiridin-2-il)-1H-imidazol-1-il]metil]-2-metil-8-propil[1,2,4]triazolo[1,5-c]pirimidina

C<sub>18</sub>H<sub>18</sub>FN<sub>7</sub>**agatolimodum**

agatolimod

*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-thymidine

agatolimod

*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-thymidine

agatolimod	<p><i>P</i>-tiotimidilil-(3'→5')-2'-desoxi-<i>P</i>-tiocitidilil-(3'→5')-2'-desoxi-<i>P</i>-tioguanilil-(3'→5')-<i>P</i>-tiotimidilil-(3'→5')-2'-desoxi-<i>P</i>-tiocitidilil-(3'→5')-2'-desoxi-<i>P</i>-tioguanilil-(3'→5')-<i>P</i>-tiotimidilil-(3'→5')-<i>P</i>-tiotimidilil-(3'→5')-<i>P</i>-tiotimidilil-(3'→5')-2'-desoxi-<i>P</i>-tioguanilil-(3'→5')-<i>P</i>-tiotimidilil-(3'→5')-2'-desoxi-<i>P</i>-tiocitidilil-(3'→5')-2'-desoxi-<i>P</i>-tioguanilil-(3'→5')-<i>P</i>-tiotimidilil-(3'→5')-<i>P</i>-tiotimidilil-(3'→5')-2'-desoxi-<i>P</i>-tioguanilil-(3'→5')-<i>P</i>-tiotimidilil-(3'→5')-2'-desoxi-<i>P</i>-tiocitidilil-(3'→5')-2'-desoxi-<i>P</i>-tioguanilil-(3'→5')-<i>P</i>-tiotimidilil-(3'→5')-2'-desoxi-<i>P</i>-tiocitidilil-(3'→5')-2'-desoxi-<i>P</i>-tioguanilil-(3'→5')-<i>P</i>-tiotimidilil-(3'→5')-timidina</p>
	C <sub>236</sub> H <sub>303</sub> N <sub>70</sub> O <sub>133</sub> P <sub>23</sub> S <sub>23</sub>
	DNA, d( <i>P</i> -thio)(T-C-G-T-C-G-T-T-T-G-T-C-G-T-T-T-G-T-C-G-T-T)
<b>alacizumabum pegolum*</b> alacizumab pegol	immunoglobulin di-Fab' fragment, anti-[ <i>Homo sapiens</i> VEGFR2 (vascular endothelial growth factor receptor 2, KDR, kinase insert domain receptor, FLK1, CD309)] pegylated humanized monoclonal antibody di-Fab' CDP791 (or g165 DFM-PEG); VH-gamma1CH1 [humanized VH ( <i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR) [8.8.10] - <i>Homo sapiens</i> IGHG1*01 CH1-hinge (hinge PPCP12-15>AA)] (220-214')-disulfide with kappa light chain [humanized V-KAPPA ( <i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR) [6.3.9] - <i>Homo sapiens</i> IGKC*01]; (226-bis-[maleimide-PEG (polyethylene glycol) 20 kDa]-226'')-dimer
alacizumab pégol	immunoglobuline fragment di-Fab', anti-[ <i>Homo sapiens</i> VEGFR2 (récepteur 2 du facteur de croissance endothélial vasculaire, KDR, récepteur à domaine insert kinase, FLK1, CD309)] anticorps monoclonal di-Fab' humanisé pégylé CDP791 (or g165 DFM-PEG); VH-gamma1CH1 [VH humanisé ( <i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR) [8.8.10] - <i>Homo sapiens</i> IGHG1*01 CH1-charnière (charnière PPCP12-15>AA)] (220-214')-disulfure avec la chaîne légère kappa [V-KAPPA humanisé ( <i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR) [6.3.9] - <i>Homo sapiens</i> IGKC*01]; dimère (226-bis-[maléimide-PEG (polyéthylène glycol) 20 kDa]-226'')
alacizumab pegol	immunoglobulina fragmento di-Fab', anti-[ <i>Homo sapiens</i> VEGFR2 (receptor 2 del factor vascular de crecimiento endotelial, KDR, receptor con dominio inserto kinasa, FLK1, CD309)] anticuerpo monoclonal di-Fab' humanizado pegilado CDP791 (o g165 DFM-PEG); VH-gamma1CH1 [VH humanizado ( <i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR) [8.8.10] - <i>Homo sapiens</i> IGHG1*01 CH1-región bisagra (región bisagra PPCP12-15>AA)] (220-214')-disulfuro con la cadena ligera kappa [V-KAPPA humanizada ( <i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR) [6.3.9] - <i>Homo sapiens</i> IGKC*01]; dimero (226-bis-[maleimida-PEG (polietilen glicol) 20 kDa]-226'')

Heavy chain / Chaîne lourde / Cadena pesada  
 EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYGMSWVROA PGKGLEWVAT 50  
 ITSGGSYTY YVDSVKGRFTI SRDNAKNTLY LQMNSLRAED TAVYYCVRIG 100  
 EDALDYWGQG TLVTVSSAST KGPSVFLAP SSKSTSGGTA ALGCLVKDYF 150  
 PEPFVTVSWS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200  
 NVNHKPSNTK VDKKVEPKSC DKTHTCAA 228

Light chain / Chaîne légère / Cadena ligera  
 DIQMTQSPSS LSASVGRVIT ITCRASQDIA GSLNWLQKPK GKAIKRLIYA 50  
 TSSLDVSGVPK RFSGSRSGSD YTLTISLQPE EDFATYYCLQ YGSPFPFTGQ 100  
 GTKVEIKRTV AAPSVEIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWVK 150  
 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKHK VYACEVTHQG 200  
 LSSPVTGSFN RGEK 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
 C22 - C96; C144 - C200; C220 and light chain C214

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación  
 Heavy chain residue C226 is the site of PEG attachment.

**aleplasininum**  
aleplasinin

2-{1-[(4-*tert*-butylphenyl)methyl]-5-(3-methylphenyl)-1*H*-indol-3-yl]-2-oxoacetic acid


aléplasinine

acide [1-[(4-(1,1-diméthyléthyl)phényl)méthyl]-5-(3-méthylphényl)-1*H*-indol-3-yl]oxoacétique

aleplasinina

ácido 2-{1-[(4-*terc*-butilfenil)metil]-5-(3-metilfenil)-1*H*-indol-3-il]-2-oxoacético

C<sub>28</sub>H<sub>27</sub>NO<sub>3</sub>



**almorexantum**  
almorexant

(2*R*)-2-[(1*S*)-6,7-dimethoxy-1-{2-[4-(trifluoromethyl)phenyl]ethyl}-3,4-dihydroisoquinolin-2(1*H*)-yl]-*N*-methyl-2-phenylacetamide


almorexant


(2*R*)-1-[(1*S*)-6,7-diméthoxy-1-{2-[4-(trifluorométhyl)phényl]éthyl}-3,4-dihydroisoquinoléin-2(1*H*)-yl]-*N*-méthyl-2-phénylacétamide



almorexant

(2*R*)-2-[(1*S*)-6,7-dimetoxi-1-{2-[4-(trifluorometil)fenil]etil}-3,4-dihidroisoquinolin-2(1*H*)-il]-*N*-metil-2-fenilacetamida

C<sub>29</sub>H<sub>31</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub>



<b>amolimogenum bepiplasmidum*</b> amolimogene bepiplasmid	plasmid DNA vector expressing a hybrid peptide consisting of a 25 amino acid targeting signal sequence fused to the N-terminus of a 236 amino acid peptide derived from fragments of the E6 and E7 genes from HPV types 16 and 18, driven by a cytomegalovirus promoter
amolimogène bépiplasmide	vecteur constitué d'ADN plasmidique exprimant un peptide hybride composé d'une séquence signal de 25 résidus fusionnée à l'acide aminé <i>N</i> -terminal d'un peptide de 236 résidus constitué de fragments du produit des gènes E6 et E7 du Papillomavirus humain de type 16 et 18 sous contrôle d'un promoteur de cytomégalovirus
amolimogén bepiplásmido	vector formado por DNA de plásmido que expresa un péptido híbrido que consiste en una secuencia señal de 25 aminoácidos unida al extremo <i>N</i> -terminal de un péptido de 236 aminoácidos constituido por fragmentos del producto de los genes E6 y E7 del Papillomavirus humano tipos 16 y 18, controlado por un promotor de cytomegalovirus
<b>amsilarotenum</b> amsilarotene	4-[3,5-bis(trimethylsilyl)benzamido]benzoic acid
amsilarotène	acide 4-[[3,5-bis(triméthylsilyl)benzoyl]amino]benzoïque
amsilaroteno	ácido 4-[[3,5-bis(trimetilsilil)benzoil]amino]benzoico
	$C_{20}H_{27}NO_3Si_2$
	
<b>anacetrapibum</b> anacetrapib	(4 <i>S</i> ,5 <i>R</i> )-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[4'-fluoro-2'-methoxy-5'-(propan-2-yl)-4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl]methyl]-4-methyl-1,3-oxazolidin-2-one
anacétrapib	(4 <i>S</i> ,5 <i>R</i> )-5-[3,5-bis(trifluorométyl)phényl]-3-[[4'-fluoro-2'-méthoxy-5'-(1-méthyléthyl)-4-(trifluorométyl)biphényl-2-yl]méthyl]-4-méthylloxazolidin-2-one
anacetrapib	(4 <i>S</i> ,5 <i>R</i> )-5-[3,5-bis(trifluorometil)fenil]-3-[[4'-fluoro-2'-metoxi-5'-(propan-2-il)-4-(trifluorometil)bifenil-2-il]metil]-4-metiloxazolidin-2-ona



**anrukinzumabum\***  
anrukinzumab


immunoglobulin G1, anti-[*Homo sapiens* interleukin 13 (IL13)] humanized monoclonal IMA-638; gamma1 heavy chain [humanized VH (*Homo sapiens* FR/*Mus musculus* CDR) [8.7.12] -*Homo sapiens* IGHG1\*03, 97R>K (CH1 120), 117L>A (CH2 1.3), 120G>A (CH2 1) (221-218')-disulfide with kappa light chain [humanized V-KAPPA (*Homo sapiens* FR/*Mus musculus* CDR) [10.3.9] -*Homo sapiens* IGKC\*01]; (227-227'':230-230'')-bisdisulfide dimer

anrukinzumab

immunoglobuline G1, anti-[*Homo sapiens* interleukine 13 (IL13)] anticorps monoclonal humanisé IMA-638; chaîne lourde gamma 1 [VH humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [8.7.12] - *Homo sapiens* IGHG1\*03, 97R>K (CH1 120), 117L>A (CH2 1.3), 120G>A (CH2 1)] (221-218')-disulfure avec la chaîne légère kappa [V-KAPPA humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [10.3.9] -*Homo sapiens* IGKC\*01]; dimère (227-227'':230-230'')-bisdisulfure

anrukinzumab

immunoglobulina G1, anti-[*Homo sapiens* interleukina 13 (IL13)] anticuerpo monoclonal humanizado IMA-638; cadena pesada gamma1 [VH humanizada (*Homo sapiens* FR/*Mus musculus* CDR) [8.7.12] - *Homo sapiens* IGHG1\*03, 97R>K (CH1 120), 117L>A (CH2 1.3), 120G>A (CH2 1)] (221-218')-disulfuro con la cadena ligera kappa [V-KAPPA humanizada (*Homo sapiens* FR/*Mus musculus* CDR) [10.3.9] -*Homo sapiens* IGKC\*01]; dímero (227-227'':230-230'')-bisdisulfuro



Heavy chain  $\gamma 1$  / Chaîne lourde  $\gamma 1$  / Cadena pesada  $\gamma 1$   
 EVQLVESGGG LVQPGGSLRL SCAASGFTFI SYAMSWVRQA PGKGLEWVAS 50  
 ISSGNTYYP DSVKGRFTIS RDNAKNSLYL QMNSLRAEDT AVYYCARLDG 100  
 YFPGFAYWQG GTLVTSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150  
 FPEPVTSWN SGALTSVHT FPAVLQSSGL YSLSSVTVTP SSSLGTQTYI 200  
 CNVNHKPSNT KVDKVEPKS CDKTHTCPPE PAPEALGAPS VFLFPPKPKD 250  
 TLMISRTPEV TCVVVDVSHS DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300  
 YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350  
 TLPSPREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTPFPVLD 400  
 SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK 448

Light chain  $\kappa$  / Chaîne légère  $\kappa$  / Cadena ligera  $\kappa$   
 DIQMTQSPSS LSASVGRVIT ITCKASESVD NYGKSLMHWY QPKPKAPKL 50'  
 LIYRASNLDS GVPDRFSGSG SGTDFTLTIS SLQPEDFATY YCQQSNEDPW 100'  
 TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150'  
 QWKVDNALQS GNSQESVTEQ DSKDSTYSLT STLTLSKADY EKHKVYACEV 200'  
 THQGLSSPVT KSFNRGEC 218'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
 22-95 22''-95'' 23'-92' 23'''-92''' 138'-198' 138'''-198''' 145-201 145''-201''  
 218'-221 218'''-221''' 227-227'' 230-230'' 262-322 262'''-322''' 368-426 368''-426''

<b>baminerceptum*</b> baminercept	human tumor necrosis factor receptor superfamily member 3 (lymphotoxin-β receptor, TNF C receptor)-(2-195)-peptide (fragment of extracellular domain) fusion protein with human immunoglobulin heavy constant γ1 chain Fc fragment [227 residues, hinge (195-205) des-(1-4),C5>V, CH2 (206-315), CH3 (316-421) des-K <sup>107</sup> ]
baminercept	membre 3 de la superfamille des récepteurs du facteur de nécrose tumorale humain (récepteur de la lymphotoxine-β ou récepteur du TNF C)-(2-195)-peptide (fragment du domaine extracellulaire) protéine de fusion avec le fragment Fc de la chaîne lourde constante γ1 de l'immunoglobuline humaine [227 résidues, dés-(1-4)-[C5>V]charnière (195-205), CH2 (206-315), des-K <sup>107</sup> -CH3 (316-421)]
baminercept	miembro 3 de la superfamilia de receptores del factor de necrosis tumoral humano (receptor de la linfoxina-β o receptor del TNF C)-(2-195)-péptido (fragmento del dominio extracelular) proteína de fusión con el fragmento Fc de la cadena pesada constante γ1 de la inmunoglobulina humana [227 restos, des(14)-[C5>V]bisagra (195-205), CH2 (206-315), desK107-CH3 (316-421)]

C<sub>4074</sub>H<sub>6282</sub>N<sub>1134</sub>O<sub>1274</sub>S<sub>68</sub>


Monomer / Monomère / Monómero					
AVPPYASENQ	TCRDQEKEYY	EPQHRICCSR	CPPGTYSYSAK	CSRIRDTVCA	50
TCAENSYNEN	WNYLTICQLC	RPCDPVMGLE	EIAPCTSKRK	TQCRCQPMGF	100
CAAWALECTH	CELLSDCPPG	TEAEKDEVG	KGNHCVFCK	AGHFQNTSSP	150
SARCQPHTRC	ENQGLVEAAP	GTAQSDTTCK	NPLEPLPEM	SGTMVDKTHT	200
CPPCPAPELL	GGPSVFLFPP	KPKDTLMISR	TPEVTCVVVD	VSHEDPEVKF	250
NWYVDGVEVH	NAKTKPREEQ	YNSTYRVVSV	LTVLHQDWLN	GKEYKCRVSN	300
KALPAPIEKT	ISKAKQPRE	PQVYTLPPSR	DELTKNQVSL	TCLVKGFYPS	350
DIAVEWESNG	QPENNYKTP	PVLDSGDSFF	LYSKLTVDKS	RWQQGNVFC	400
SVMHEALHNN	YTKKSLSP	G			421

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
 12-27 12'-27' 28-41 28'-41' 31-49 31'-49' 52-67 52'-67' 70-85  
 70'-85' 73-93 73'-93' 95-101 95'-101' 108-117 108'-117' 111-136 111'-136'  
 139-154 139'-154' 201-201' 204-204' 236-296 236'-296' 342-400 342'-400'

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación  
 Asn-9 Asn-9' Asn-146 Asn-146' Asn-272 Asn-272'

<b>bentamapimodum</b> bentamapimod	2-(1,3-benzothiazol-2-yl)-2-[2-({4-[(morpholin-4-yl)methyl]phenyl}=methoxy)pyrimidin-4-yl]acetonitrile
bentamapimod	(benzothiazol-2-yl)[2-({4-[(morpholin-4-yl)méthyl]phényl}=méthoxy)pyrimidin-4-yl]acétonitrile
bentamapimod	2-(1,3-benzotiazol-2-il)-2-[2-({4-[(morfolin-4-il)metil]fenil}metoxi)=pirimidin-4-il]acetónitrilo

C<sub>25</sub>H<sub>23</sub>N<sub>5</sub>O<sub>2</sub>S



**berubicinum**


berubicin

(8*S*,10*S*)-10-[(3-amino-4-*O*-benzyl-2,3,6-trideoxy- $\alpha$ -L-lyxo-hexopyranosyl)oxy]-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione

bérubicine

(8*S*,10*S*)-10-[(3-amino-4-*O*-benzyl-2,3,6-tridéoxy- $\alpha$ -L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tétrahydro-6,8,11-trihydroxy-8-(hydroxyacétyl)-1-méthoxytétracène-5,12-dione

berubicina

(8*S*,10*S*)-10-[(3-amino-4-*O*-benzil-2,3,6-tridesoxi- $\alpha$ -L-lixo-hexopiranosil)oxi]-6,8,11-trihidroxil-8-(hidroxiacetil)-1-metoxil-7,8,9,10-tetrahidrotetraceno-5,12-dionaC<sub>34</sub>H<sub>35</sub>NO<sub>11</sub>**besifloxacinum**


besifloxacin

7-[(3*R*)-3-aminoazepan-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

bésifloxacine

(+)acide 7-[(3*R*)-3-aminohexahydro-1*H*-azépin-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoléine-3-carboxylique

besifloxacino

ácido 7-[(3*R*)-3-aminoazepan-1-il]-1-ciclopropil-8-cloro-6-fluoro-4-oxo-1,4-dihidroquinolina-3-carboxílicoC<sub>19</sub>H<sub>21</sub>ClFN<sub>3</sub>O<sub>3</sub>**betrixabanum**

betrixaban

*N*-(5-chloropyridin-2-yl)-2-[4-(*N,N*-dimethylcarbamimidoyl)benzamido]-5-methoxybenzamide


bétrixaban

*N*-(5-chloropyridin-2-yl)-2-[(4-[(diméthylamino)iminométhyl]benzoyl)amino]-5-méthoxybenzamide

betrixabán

*N*-(5-cloropiridin-2-il)-2-[4-(*N,N*-dimetilcarbamidoil)benzamido]-5-metoxibenzamida



C<sub>23</sub>H<sub>22</sub>ClN<sub>5</sub>O<sub>3</sub>

**briobaceptum\***  
briobacept

aspartyl[1-valine,20-asparagine,27-proline](human tumor necrosis factor receptor superfamily member 13C (BAFF receptor, BlyS receptor 3 or CD268 antigen)-(1-71)-peptidyl (part of the extracellular domain))valyl(human immunoglobulin G1 Fc fragment, *Homo sapiens*IGHG1-(104-329)-peptide) (79-79':82-82')-bisdisulfide dimer

briobacept

aspartyl[1-valine,20-asparagine,27-proline](membre 13C de la superfamille des récepteurs du facteur de nécrose tumorale humain (récepteur du BAFF, récepteur 3 du BlyS ou antigène CD268)-(1-71)-peptidyl (fragment du domaine extracellulaire))valyl(fragment Fc de l'immunoglobuline G1 humaine, *Homo sapiens*IGHG1-(104-329)-peptide) (79-79':82-82')-bisdisulfure du dimère

briobacept

aspartil[1-valina,20-asparagina,27-prolina](miembro 13C de la superfamilia de receptores del factor de necrosis tumoral humano (receptor del BAFF, receptor 3 del BlyS o antígeno CD268)-(1-71)-peptidil (fragmento del dominio extracelular))valil(fragmento Fc de la inmunoglobulina G1 humana, *Homo sapiens*IGHG1-(104-329)-péptido) (79-79':82-82')-bisdisulfuro del dímero

C<sub>2910</sub>H<sub>4542</sub>N<sub>814</sub>O<sub>876</sub>S<sub>24</sub>

Monomer / Monomère / Monómero

DVRRGPRSLR	GRDAPAPTPC	NPAECFDPLV	RHCVACGLLR	TPRKPAGAS	50
SPAPRTALQP	QESVGAGAGE	AAVDKTHTCP	PCPAPELLGG	PSVFLFPKP	100
KDTLMISRTP	EVTCTVVVDVS	HEDPEVKFNW	YVDGVEVHNA	KTKPREEQYN	150
STYRVVSVLT	VLHQDWLNGK	EYCKVSNKA	LPAPIEKTIS	KAKQPREPQ	200
VYTLPPSRDE	LTKNQVSLTC	LVKGFYPSDI	AVEWESNGQP	ENNYKTTPPV	250
LDSDGSFFLY	SKLTVDKSRW	QQGNVFSCSV	MHEALHNHYT	QKSLSLSPG	249

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

20-33 20'-33' 25-36 25'-36' 79-79' 82-82' 114-174 114'-174' 220-278 220'-278'

**cabazitaxelum**  
cabazitaxel


1-hydroxy-7β,10β-dimethoxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-[(2*R*,3*S*)-3-[[*tert*-butoxy)carbonyl]amino]-2-hydroxy-3-phenylpropanoate]

cabazitaxel

(-)-12b-acétate 12-benzoate et 9-[(2*R*,3*S*)-3-[[1,1-diméthyléthoxy)carbonyl]amino]-2-hydroxy-3-phénylpropanoate] de (2*aR*,4*S*,4*aS*,6*R*,9*S*,11*S*,12*S*,12*aR*,12*bS*)-11-hydroxy-4,6-diméthoxy-4*a*,8,13,13-tétraméthyl-5-oxo-3,4,4*a*,5,6,9,10,11,12,12*a*-décahydro-7,11-méthano-1*H*-cyclodéca[3,4]benzo[1,2-*b*]oxète-9,12,12*b*(2*aH*)-triyle

cabazitaxel

4-acetato 2-benzoato 13-[(2*R*,3*S*)-3-[[*tert*-butoxi)carbonil]amino]-2-hidroxipropanoato] de 1-hidroxi-7β,10β-dimetoxi-9-oxo-5β,20-epoxitax-11-eno-2α,4,13α-triil

C<sub>45</sub>H<sub>57</sub>NO<sub>14</sub>

**cariprazinum**  
cariprazine


3-(*trans*-4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl)-1,1-dimethylurea

cariprazine

*N'*-(*trans*-4-[2-[4-(2,3-dichlorophényl)pipérazin-1-yl]éthyl]cyclohexyl)-*N,N*-diméthylurée

cariprazina

*N'*-(*trans*-4-[2-[4-(2,3-diclorofenil)piperazin-1-il]etil]ciclohexil)-*N,N*-dimetilurea

C<sub>21</sub>H<sub>32</sub>Cl<sub>2</sub>N<sub>4</sub>O

**carmegliptinum**  
carmegliptin


(4*S*)-1-[(2*S*,3*S*,11*bS*)-2-amino-9,10-dimethoxy-1,3,4,6,7,11*b*-hexahydro-2*H*-benzo[*a*]quinolizin-3-yl]-4-(fluoromethyl)pyrrolidin-2-one

carmégliptine

(4*S*)-1-[(2*S*,3*S*,11*bS*)-2-amino-9,10-diméthoxy-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrido[2,1-*a*]isoquinoléin-3-yl]-4-(fluorométhyl)pyrrolidin-2-one

carmegliptina

(4*S*)-1-[(2*S*,3*S*,11*bS*)-2-amino-9,10-dimetoxi-1,3,4,6,7,11*b*-hexahidro-2*H*-benzo[*a*]quinolizin-3-il]-4-(fluorometil)pirrolidin-2-ona

C<sub>20</sub>H<sub>28</sub>FN<sub>3</sub>O<sub>3</sub>

**cobiprostonum**


cobiprostone

7-((2*R*,4*aR*,5*R*,7*aR*)-2-[(3*S*)-1,1-difluoro-3-methylpentyl]-2-hydroxy-6-oxooctahydrocyclopenta[*b*]pyran-5-yl)heptanoic acid

cobiprostone

acide 7-((2*R*,4*aR*,5*R*,7*aR*)-2-[(3*S*)-1,1-difluoro-3-methylpentyl]-2-hydroxy-6-oxooctahydrocyclopenta[*b*]pyran-5-yl)heptanoïque

cobiprostona

ácido 7-((2*R*,4*aR*,5*R*,7*aR*)-2-[(3*S*)-1,1-difluoro-3-metilpentil]-2-hidroxi-6-oxooctahidrociclopenta[*b*]piran-5-il)heptanoicoC<sub>21</sub>H<sub>34</sub>F<sub>2</sub>O<sub>5</sub>**conestatium alfa\***

conestat alfa

human plasma protease C1 inhibitor (C1 esterase inhibitor)  
(*N*,*O*-glycosylated recombinant protein expressed in the mammary gland of transgenic rabbits), glycoform  $\alpha$ 

conestat alfa

inhibiteur de la protéase plasmatique C1 humain (inhibiteur de l'estérase C1) (protéine *N*,*O*-glycosylée recombinante exprimée dans la glande mammaire de lapines transgéniques), glycoforme  $\alpha$ 

conestat alfa

inhibidor de la proteasa plasmática C1 humana (inhibidor de la esterasa C1) (proteína *N*,*O*-glicosilada recombinante expresada en glándula mamaria de coneja transgénica), glicoforma  $\alpha$ C<sub>2355</sub>H<sub>3745</sub>N<sub>613</sub>O<sub>726</sub>S<sub>17</sub>

NPNATSSSSQ	DPESLQDRGE	GKVATTIVISK	MLFVEPILEV	SSLPTTNSTT	50
NSÄTKITANT	TDEPTTQPTT	EPTTQPTIQP	TQPTTQLPTD	SPTQPTTGSF	100
CPGPVTLCSQ	LESHSTEAVL	GDALVDFSLK	LYHAFSAMKK	VETNMAFSPF	150
SIASLLTQVL	LGAGENTKTN	LESILSYPKD	FTCVHQALKG	FTTKGVTSVS	200
QIFHSPDLAI	RDTFVNASRT	LYSSSPRVLS	NNSDANLELI	NTWVAKNTNN	250
KISRLLDGLP	SDTRLVLLNA	IYLSAKWKT	FDPKTRMEP	FHFKNVIVK	300
PMMNSKYPV	AHFIDQTLKA	KVGLQLSHN	LSLVILVPQN	LKHRLEDMQ	350
ALSPSVFKAI	MEKLEMSKFQ	PTLLTLPRIK	VTTSQDMLSI	MEKLEFFDFS	400
YDLNLCGLTE	DPDLQVSAMQ	HQTVLELTET	GVEAAAASAI	SVARTLLVFE	450
VQQPFLFVLW	DQQHKFPVFM	GRVYDPRA			478

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
101-406 108-183

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación

Asn-3 Thr-26 Ser-42 Asn-47 Thr-49 Asn-59 Thr-61  
Thr-66 Thr-70 Thr-74 Asn-216 Asn-231 Asn-250 Asn-330

**dacetuzumabum\***

dacetuzumab

immunoglobulin G1, anti-[*Homo sapiens* CD40 (TNF receptor superfamily member 5, TNFRSF5)] humanized monoclonal SGN-40 (or huS2C6); gamma1 heavy chain [humanized VH (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.7] -*Homo sapiens* IGHG1\*03, 97R>K (CH1 120)] (217-219')-disulfide with kappa light chain humanized V-KAPPA (*Homo sapiens* FR/*Mus musculus* CDR) [11.3.9] -*Homo sapiens* IGKC\*01]; (223-223":226-226")-bisdisulfide dimer

dacétuzumab

immunoglobuline G1, anti-[*Homo sapiens* CD40 (membre 5 de la superfamille des récepteurs du TNF, TNFRSF5)] anticorps monoclonal humanisé SGN-40 (ou huS2C6); chaîne lourde gamma1 [VH humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.7] -*Homo sapiens* IGHG1\*03, 97R>K (CH1 120)] (217-219')-disulfure avec la chaîne légère kappa [V-KAPPA humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [11.3.9] -*Homo sapiens* IGKC\*01]; dimère (223-223":226-226")-bisdisulfure

dacetuzumab

immunoglobulina G1, anti-[*Homo sapiens* CD40 (miembro 5 de la superfamilia de receptores del TNF, TNFRSF5)] anticuerpo monoclonal humanizado SGN-40 (o huS2C6); cadena pesada gamma1 [VH humanizado (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.7] - *Homo sapiens* IGHG1\*03, 97R>K (CH1 120)] (217-219')-disulfuro con la cadena ligera kappa [V-KAPPA humanizada (*Homo sapiens* FR/*Mus musculus* CDR) [11.3.9] -*Homo sapiens* IGKC\*01]; dímero (223-223":226-226")-bisdisulfuro

C<sub>6452</sub>H<sub>9964</sub>N<sub>1732</sub>O<sub>1998</sub>S<sub>42</sub>

Heavy chain / Chaîne lourde / Cadena pesada  
 EVQLVESGGG LVQPQGSRLR SCAASGYSFT GYYIHWVRQA PGKGLEWVAR 50  
 VIPNAGGTSY NQKFKGRFTL SVDNSKNTAY LQMNSLRAED TAVVYCAREG 100  
 IYWWGQGLTV TVSSASTKGP SVFPLAPSSK STSGGTAALG CLVKDYFPEP 150  
 VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL GTQTYICINVN 200  
 HKPSNTKVDK KVEPKSCDKT HTPCPCPAPE LLGGPSVFLF PPKPKDTLMI 250  
 SRTPEVTCVV VDVSHEDPEV KFNWVVDGVE VHNAKTKPRE EQYNSTYRVV 300  
 SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP REPQVYTLPP 350  
 SREEMTKNQV SLTCLVKGfy PSDIAVENES NGQPENNYKT TTPVLDSDGS 400  
 FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKLSL SPGK 444

Light chain / Chaîne légère / Cadena ligera  
 DIQMTQSPSS LSASVGRVIT ITCRSSQSLV HSNGNFTLHW YQQKPKGKPK 50'  
 LLLYTVSNRF SGVPSRFSGS GSGTDFTLTI SSLQPEDFAT YFCSQTHVP 100'  
 WTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVCL LNNFYPREAK 150'  
 VQWKVDNALQ SGNSQESVTE QDSKDYSTSL SSTLTLSKAD YEKHKVYACE 200'  
 VTHQGLSSPV TKSFNRGEC 219'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
 22-96 22"-96" 23'-93" 23"-93" 139'-199' 139"-199" 141-197 141"-197"  
 217-219' 217"-219" 223-223" 226-226" 258-318 258"-318" 364-422 364"-422"

**daporinadum**

daporinad


(2*E*)-*N*-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)prop-2-enamide

daporinad

(2*E*)-*N*-[4-(1-benzoylpipéridin-4-yl)butyl]-3-(pyridin-3-yl)prop-2-énamide

daporinad

(2*E*)-*N*-[4-(1-benzoilpiperidin-4-il)butil]-3-(piridin-3-il)prop-2-enamida

C<sub>24</sub>H<sub>29</sub>N<sub>3</sub>O<sub>2</sub>

**darinaparsinum**


darinaparsin

L- $\gamma$ -glutamyl-S-(dimethylarsanyl)-L-cysteinylglycine

darinaparsine

L- $\gamma$ -glutamyl-S-(diméthylarsanyl)-L-cystéinylglycine

darinaparsina

L- $\gamma$ -glutamyl-S-(dimetilarsanil)-L-cisteinilglicina $C_{12}H_{22}AsN_3O_6S$ **dexneбиволolum**


dexneбиволol

(1*R*)-2-((2*R*)-2-[(2*S*)-6-fluoro-3,4-dihydro-2*H*-chromen-2-yl]-2-hydroxyethyl)amino)-1-[(2*R*)-6-fluoro-3,4-dihydro-2*H*-chromen-2-yl]ethanol

dexnéбиволol

(1*R*,1'*R*)-1,1'-[(2*R*,2'*S*)-bis(6-fluoro-3,4-dihydro-2*H*-1-benzopyran-2-yl)]-2,2'-azanediyldiéthanol

dexneбиволol

(1*R*)-2-((2*R*)-2-[(2*S*)-6-fluoro-3,4-dihydro-2*H*-chromen-2-yl]-2-hydroxiethyl)amino)-1-[(2*R*)-6-fluoro-3,4-dihydro-2*H*-chromen-2-yl]etanol $C_{22}H_{25}F_2NO_4$ **emricasanum**


emricasan

(3*S*)-3-((2*S*)-2-[*N*-(2-*tert*-butylphenyl)oxamoylamino]propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid

emricasan

acide (3*S*)-3-((2*S*)-2-[[2-(1,1-diméthyléthyl)phényl]amino]=oxoacétyl)amino]propanoyl)amino)-4-oxo-5-(2,3,5,6-tétrafluorophénoxy)pentanoïque

emricasán

ácido (3*S*)-3-((2*S*)-2-[*N*-(2-*terc*-butilfenil)oxamoilamino]=propanamido)-4-oxo-5-(2,3,5,6-tetrafluorofenoxi)pentanoico $C_{26}H_{27}F_4N_3O_7$ 

**eribaxaban**


eribaxaban

(2*R*,4*R*)-*N*<sup>1</sup>-(4-chlorophenyl)-*N*<sup>2</sup>-[2-fluoro-4-(2-oxopyridin-1(2*H*)-yl)phenyl]-4-methoxy pyrrolidine-1,2-dicarboxamide

éribaxaban

(2*R*,4*R*)-*N*<sup>1</sup>-(4-chlorophényl)-*N*<sup>2</sup>-[2-fluoro-4-(2-oxopyridin-1(2*H*)-yl)phényl]-4-méthoxy pyrrolidine-1,2-dicarboxamide

eribaxabán

(2*R*,4*R*)-*N*<sup>1</sup>-(4-clorofenil)-*N*<sup>2</sup>-[2-fluoro-4-(2-oxopiridin-1(2*H*)-il)fenil]-4-metoxipirrolidina-1,2-dicarboxamidaC<sub>24</sub>H<sub>22</sub>ClFN<sub>4</sub>O<sub>4</sub>**ezatiostatam**


ezatiostat

ethyl [(4*S*)-4-amino-5-ethoxy-5-oxopentanoyl]-*S*-benzyl-L-cysteinyl-D-2-phenylglycinate

ézatiostat

(2*R*)-[(4*S*)-4-amino-5-éthoxy-5-oxopentanoyl]-*S*-benzyl-L-cystéinyl-2-phénylglycinate d'éthyle

ezatiostat

(2*R*)-[(4*S*)-4-amino-5-etoxi-5-oxopentanoil]-*S*-bencil-L-cisteinil-2-fenilglicinato de etiloC<sub>27</sub>H<sub>35</sub>N<sub>3</sub>O<sub>6</sub>S**fasobegronum**


fasobegron

4'-[2-[[2*R*]-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl)-3-methoxy-[1,1'-biphenyl]-4-carboxylic acid

fasobégron

acide 4'-[2-[[2*R*]-2-(3-chlorophényl)-2-hydroxyéthyl]amino]éthyl)-3-méthoxybiphényle-4-carboxylique

fasobegrón

ácido 4'-[2-[[2*R*]-2-(3-clorofenil)-2-hidroxietil]amino]etil)-[1,1'-bifenil]-3-metoxi-4-carboxílicoC<sub>24</sub>H<sub>24</sub>ClNO<sub>4</sub>

**favipiravirum**

favipiravir


6-fluoro-3-hydroxypyrazine-2-carboxamide

favipiravir

6-fluoro-3-hydroxypyrazine-2-carboxamide

favipiravir

6-fluoro-3-hidroxipirazina-2-carboxamida

 $C_5H_4FN_3O_2$ **fermagatum**

fermagate


diiron(III) tetramagnesium carbonate dodecahydroxide—water (1/4)

fermagate

tétrahydrate de carbonate et bis[(OC-6-11)-hexahydroxyferrate(3<sup>-</sup>)] de tétramagnésium

fermagato

dodecahidróxidocarbonato de dihierro(III) y tetramagnesio—agua(1/4)

 $CH_{12}Fe_2Mg_4O_{15} \cdot 4 H_2O$ **flopristinum**


flopristin

(3*R*,4*R*,5*E*,10*E*,12*E*,14*S*,16*R*,26*aR*)-16-fluoro-14-hydroxy-4,12-dimethyl-3-(propan-2-yl)-3,4,8,9,14,15,16,17,24,25,26,26a-dodecahydro-1*H*,7*H*,22*H*-21,18-azepirrolo=[2,1-*c*][1,8,4,19]dioxadiazacyclotetracosine-1,7,22-trione

flopristine

(3*R*,4*R*,5*E*,10*E*,12*E*,14*S*,16*R*,26*aR*)-16-fluoro-14-hydroxy-4,12-diméthyl-3-(1-méthyléthyl)-8,9,14,15,16,17,24,25,26,26a-décahydro-3*H*-21,18-nitrilo-1*H*,22*H*-pyrrolo=[2,1-*c*][1,8,4,19]dioxadiazacyclotétracosine-1,7,22(4*H*)-trione

flopristina

(3*R*,4*R*,5*E*,10*E*,12*E*,14*S*,16*R*,26*aR*)-16-fluoro-14-hidroxi-4,12-dimetil-3-(propan-2-il)-3,4,8,9,14,15,16,17,24,25,26,26a-dodecahidro-1*H*,7*H*,22*H*-21,18-azepirrolo=[2,1-*c*][1,8,4,19]dioxadiazacyclotetracosina-1,7,22-triona $C_{28}H_{38}FN_3O_6$ 

**folitixorinum**

folitixorin


*N*-{4-[(6*aRS*)-3-amino-1-oxo-1,4,5,6,6*a*,7-hexahydroimidazo[1,5-*f*]pteridin-8(9*H*)-yl]benzoyl}-L-glutamic acid

folitixorine

acide *N*-{4-[(6*aRS*)-3-amino-1-oxo-1,4,5,6,6*a*,7-hexahydroimidazo[1,5-*f*]ptéridin-8(9*H*)-yl]benzoyl}-L-glutamique

folitixorina

ácido *N*-{4-[(6*aRS*)-3-amino-1-oxo-1,4,5,6,6*a*,7-hexahydroimidazo[1,5-*f*]pteridin-8(9*H*)-il]benzoil]-L-glutámico

C<sub>20</sub>H<sub>23</sub>N<sub>7</sub>O<sub>6</sub>**ibodutantum**

ibodutant


6-methyl-*N*-{1-[(1*R*)-1-[(1-[(tetrahydro-2*H*-pyran-4-yl)methyl]piperidin-4-yl)methyl]amino]-3-phenyl-1-oxopropan-2-yl]amino}carbonylcyclopentyl}-1-benzothiophene-2-carboxamide

ibodutant

*N*-[1-[(1*R*)-1-benzyl-2-oxo-2-[(1-[(tétrahydro-2*H*-pyran-4-yl)méthyl]pipéridin-4-yl)méthyl]amino]éthyl]carbamoylecyclopentyle]-6-méthyl-1-benzothiophène-2-carboxamide

ibodutant

*N*-[1-[(1*R*)-1-bencil-2-oxo-2-[(1-[(tetrahydro-2*H*-piran-4-il)metil]pipéridin-4-il)metil]amino]etil]carbamoil]ciclopentil]-6-metil-1-benzotiofeno-2-carboxamida

C<sub>37</sub>H<sub>48</sub>N<sub>4</sub>O<sub>4</sub>S**imeglimum**

imeglimin


(4*R*)-6-(dimethylamino)-4-methyl-4,5-dihydro-1,3,5-triazin-2-amine

iméglimine



(+)-(6*R*)-1,6-dihydro-*N,N*,6-triméthyl-1,3,5-triazine-2,4-diamine


imeglimina

(4*R*)-6-(dimetilamino)-4-metil-4,5-dihidro-1,3,5-triazin-2-amina

C<sub>6</sub>H<sub>13</sub>N<sub>5</sub>



<b>laromustinum</b> laromustine	2-(2-chloroethyl)-1,2-bis(methanesulfonyl)- <i>N</i> -methylhydrazinecarboxamide
laromustine	2'-(2-chloroéthyl)- <i>N</i> -méthyl-1',2'-bis(méthylsulfonyl)= carbamohydrazide
laromustina	2-(2-cloroetil)-1,2-bis(metanosulfonyl)- <i>N</i> -metilhidrazinacarboxamida  C <sub>6</sub> H <sub>14</sub> ClN <sub>3</sub> O <sub>5</sub> S <sub>2</sub>
	
<b>levonebivololum</b> levonebivolol	(1 <i>S</i> )-2-({(2 <i>S</i> )-2-[(2 <i>R</i> )-6-fluoro-3,4-dihydro-2 <i>H</i> -chromen-2-yl]- 2-hydroxyethyl}amino)-1-[(2 <i>S</i> )-6-fluoro-3,4-dihydro-2 <i>H</i> -chromen- 2-yl]ethanol
lévonébivolol	(1 <i>S</i> ,1' <i>S</i> )-1,1'-[(2 <i>R</i> ,2' <i>S</i> )-bis(6-fluoro-3,4-dihydro-2 <i>H</i> -1-benzopyran- 2-yl)]-2,2'-azanediyldiéthanol
levonebivolol	(1 <i>S</i> )-2-({(2 <i>S</i> )-2-[(2 <i>R</i> )-6-fluoro-3,4-dihydro-2 <i>H</i> -cromen-2-il]- 2-hidroxietyl}amino)-1-[(2 <i>S</i> )-6-fluoro-3,4-dihydro-2 <i>H</i> -cromen- 2-il]etanol  C <sub>22</sub> H <sub>25</sub> F <sub>2</sub> NO <sub>4</sub>
	
<b>linopristinum</b> linopristin	<i>N</i> -{(6 <i>R</i> ,9 <i>S</i> ,10 <i>R</i> ,13 <i>S</i> ,15 <i>aS</i> ,22 <i>S</i> ,24 <i>aS</i> )-22-[[4-( dimethylamino)phenyl]methyl]-6-ethyl-10,23-dimethyl- 18-[(morpholin-4-yl)methyl]-5,8,12,15,21,24-hexaoxo-13-phenyl- 1,2,3,5,6,7,8,9,10,11,12,13,14,15,15 <i>a</i> ,16,19,21,22,23,24,24 <i>a</i> - docosahydropyrido[2,1- <i>f</i> ]pyrrolo[2,1- <i>h</i> ][1,4,7,10,13,16]= oxapentaazacyclonadecin-9-yl]-3-hydroxypyridine-2-carboxamide
linopristine	(6 <i>R</i> ,9 <i>S</i> ,10 <i>R</i> ,13 <i>S</i> ,15 <i>aS</i> ,22 <i>S</i> ,24 <i>aS</i> )-22-[[4-(diméthylamino)= phényl]méthyl]-6-éthyl-9-[[3-hydroxypyridin-2-yl]carbonyl]amino)- 10,23-diméthyl-18-[(morpholin-4-yl)méthyl]-13-phényl- 1,2,3,6,7,9,10,13,14,16,19,22,23,24 <i>a</i> -tétradécahydro- 12 <i>H</i> -pyrido[2,1- <i>f</i> ]pyrrolo[2,1- <i>h</i> ][1,4,7,10,13,16]= oxapentaazacyclonadécine-5,8,12,15,21,24(15 <i>aH</i> )-hexone
linopristina	<i>N</i> -{(6 <i>R</i> ,9 <i>S</i> ,10 <i>R</i> ,13 <i>S</i> ,15 <i>aS</i> ,22 <i>S</i> ,24 <i>aS</i> )-22-[[4-(dimetilamino)fenil]= metil]-6-etil-13-fenil-10,23-dimetil-18-[(morfolin-4-il)metil]- 5,8,12,15,21,24-hexaoxo- 1,2,3,5,6,7,8,9,10,11,12,13,14,15,15 <i>a</i> ,16,19,21,22,23,24,24 <i>a</i> - docosahidropirido[2,1- <i>f</i> ]pirrolo[2,1- <i>h</i> ][1,4,7,10,13,16]= oxapentaazaciclolonadecin-9-il]-3-hidroxipiridina-2-carboxamida

C<sub>50</sub>H<sub>63</sub>N<sub>9</sub>O<sub>10</sub>

lucatumumabum\*  
lucatumumab

immunoglobulin G1, anti-[*Homo sapiens* CD40 (TNF receptor superfamily member 5, TNFRSF5)] human monoclonal antibody CHIR-12.12; gamma1 heavy chain [*Homo sapiens* VH [8.8.13] -IGHG1\*03 (CH1 S10>A), no C-terminal lysine] from clone CHIR-12.12 (223-219')-disulfide with kappa light chain [*Homo sapiens* V-KAPPA (IGKV2-28-IGJK3\*01, K12>R) [11.3.9] -IGKC\*01] from clone CHIR-12.12; (229-229':232-232'')-bisdisulfide dimer

lucatumumab

immunoglobuline G1, anti-[*Homo sapiens* CD40 (membre 5 de la superfamille des récepteurs du TNF, TNFRSF5)] anticorps monoclonal humain CHIR-12.12; chaîne lourde gamma1 [*Homo sapiens* VH [8.8.13] -IGHG1\*03 (CH1 S10>A), pas de lysine C-terminale] du clone CHIR-12.12 (223-219')-disulfure avec la chaîne légère kappa [*Homo sapiens* V-KAPPA (IGKV2-28-IGJK3\*01, K12>R) [11.3.9] -IGKC\*01] du clone CHIR-12.12; dimère (229-229':232-232'')-bisdisulfure

lucatumumab

immunoglobulina G1, anti-[*Homo sapiens* CD40 (miembro 5 de la superfamilia de receptores del TNF, TNFRSF5)] anticuerpo monoclonal humano CHIR-12.12; cadena pesada gamma1 [*Homo sapiens* VH [8.8.13] -IGHG1\*03 (CH1 S10>A), sin lisina C-terminal] del clon CHIR-12.12 (223-219')-disulfuro con la cadena ligera kappa [*Homo sapiens* V-KAPPA (IGKV2-28-IGJK3\*01, K12>R) [11.3.9] -IGKC\*01] del clon CHIR-12.12; dímero (229-229':232-232'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada					
QVQLVESGGG	VVQPGRLRL	SCAASGFTFS	SYGMHWVRQA	PGKLEWVAV	50
ISYEESNRH	ADSVKGRFTI	SRDNSKITLY	LQMNSLRTE	TAVYICARDG	100
GIAAPGPDYW	GQGLTIVTSS	ASTKGPSVFP	LAPASKSTSG	GTAALGCLVK	150
DYFPEPVTVS	WNSGALTSV	HTFPVAVLQSS	GLYSLSVVT	VPSSSLGTQT	200
YICNVNHKPS	NTKVDKRVPE	KSCDKTHTCP	PCPAPPELLGG	PSVFLFPPPKP	250
KDTLMISRTP	EVTQVVVDVS	HEDPEVKFNW	YVDGVEVHNA	KTKPREPEQYN	300
STYRVVSVLT	VLHQDWLNGK	EYKCKVSNKA	LPAPIEKTIIS	KAKGQPREPQ	350
VYTLPPSREE	MTKNQVSLTC	LVKGFYPSDI	AVEWESNGQP	ENNYKTTTPPV	400
LDSGGSFFLY	SKLTVDKSRW	QQGNVFCSCV	MHEALHNYHT	QKSLSLSPGK	450
Light chain / Chaîne légère / Cadena ligera					
DIVMTQSPLS	LTVTTPGEPAS	ISCRSSQSLL	YSNGYNYLDW	YLQKPGQSPQ	50
VLISLGSNRA	SGVPDRFSGS	GSGLDFTLKI	SRVEAEDVGV	YYCMQARQTP	100
FTFGPGTKVD	IRRTVAAPSV	FIFPPSDEQL	KSGTASVCL	LNNFYPREAK	150
VQWKVDNALQ	SGNSQESVTE	QDSKSTYSYL	SSTLTLSKAD	YEKHKVYACE	200
VTHQGLSSPV	TKSFNRGEC				219

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Light Chain Intrachain: C23-C93, C149-C199

Heavy Chain Intrachain: C22-C96, C147-C203, C264-C324, C369-C428

Interchain: Light Chain: C219-Heavy Chain 223, Heavy Chain 1 C229-Heavy Chain 2 C229,

Heavy Chain 1 C232 - Heavy Chain 2 C232

<b>milatuzumabum*</b> milatuzumab	immunoglobulin G1, anti-[ <i>Homo sapiens</i> CD74 (major histocompatibility complex class II invariant chain)] humanized monoclonal IMMU-115 (or hLL1); gamma1 heavy chain [humanized VH ( <i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR) [8.8.13] - <i>Homo sapiens</i> IGHG1*03] (223-219')-disulfide with kappa light chain [humanized V-KAPPA ( <i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR) [11.3.9] - <i>Homo sapiens</i> IGKC*01]; (229-229'':232-232'')-bisdisulfide dimer
milatuzumab	immunoglobuline G1, anti-[ <i>Homo sapiens</i> CD74 (chaîne invariante du complexe majeur d'histocompatibilité de classe II)] anticorps monoclonal humanisé IMMU-115 (ou hLL1); chaîne lourde gamma1 [VH humanisé ( <i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR) [8.8.13] - <i>Homo sapiens</i> IGHG1*03] (223-219')-disulfure avec la chaîne légère kappa [V-KAPPA humanisé ( <i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR) [11.3.9] - <i>Homo sapiens</i> IGKC*01]; dimère (229-229'':232-232'')-bisdisulfure
milatuzumab	immunoglobulina G1, anti-[ <i>Homo sapiens</i> CD74 (cadena invariable del complejo mayor de histocompatibilidad de clase II)] anticuerpo monoclonal humanizado IMMU-115 (o hLL1); cadena pesada gamma1 [VH humanizado ( <i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR) [8.8.13] - <i>Homo sapiens</i> IGHG1*03] (223-219')-disulfuro con la cadena ligera kappa [V-KAPPA humanizada ( <i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR) [11.3.9] - <i>Homo sapiens</i> IGKC*01]; dímero (229-229'':232-232'')-bisdisulfuro

C<sub>6518</sub>H<sub>10066</sub>N<sub>1758</sub>O<sub>2020</sub>S<sub>40</sub>

Heavy chain / Chaîne lourde / Cadena pesada

QVQLQSGSE	LKKPGASVKV	SCKASGYTFT	NYGVNWIQQA	PQQQLQWMCW	50
INPNTGPTF	DDDFKGRFAP	SLDTSVSTAY	LQISLAKADD	TAVYFCSRSR	100
GKNEAWFAYW	QQTLLVTVSS	ASTKCPVFP	LAPSSKSTSG	GTAALGCLVK	150
DYFPEPVTVS	WNSGALTSGV	HTPFAVLQSS	GLYSLSSVVT	VPSSSLGTQT	200
YICNVNHKPS	NTKVDKRVFP	KSCDKTHTCP	PCPAPELLGG	PSVFLFPPPK	250
KDTLMLISRT	EVTCTVVVDVS	HEDEPKVFNW	YVDGVEVHNA	KTKRREEQYN	300
STYRVVSVLT	VLHODWLNKG	EYKCKVSNKA	LPAPIEKTIS	KAKGQPREPQ	350
VYTLPPSREE	MTKNQVSLTC	LVKGFYPSDI	AVENESNGQP	ENNYKTTTPV	400
LDSGGSFPLY	SKLTVDKSRW	QQGNVFSCSV	MHEALHNHYT	QKSLSLSPGK	450

Light chain / Chaîne légère / Cadena ligera


DIQLTQSPLS	LPVTLGQPAS	ISCRSSQSLV	HRNGNTYLHW	FQQRPGQSPR	50
LLIYTVSNRF	SGVPDRFSGS	SGSTDFTLKI	SRVEAEDVGV	YFCSQSSHVP	100
PTFGAGTRLE	IKRTVAAPSV	FIFPPSDEQL	KSGTASVCL	LNNFYPREAK	150
VQWKVDNALQ	SGNSQESVTE	QDSKSTVSL	SSTLTLSKAD	YEKHKVYACE	200
VTHQGLSSPV	TKSFNRGEC				219

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

22-96 22'-96" 23'-93' 23''-93''' 139'-199' 139''-199''' 147-203 147''-203'''  
219'-223 219''-223'' 229-229'' 232-232'' 264-324 264''-324'' 370-428 370''-428''

<b>mirabegronum</b> mirabegron	2-(2-amino-1,3-thiazol-4-yl)-N-[4-(2-((2R)-2-hydroxy-2-phenylethyl)=amino)ethyl)phenyl]acetamide
mirabégon	2-(2-aminothiazol-4-yl)-N-[4-(2-((2R)-2-hydroxy-2-phényléthyl)=amino)éthyl]phényl]acétamide
mirabegrón	2-(2-amino-1,3-tiazol-4-il)-N-[4-(2-((2R)-2-fenil-2-hidroxietil)amino)=etil]fenil]acetamida

C<sub>21</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub>S



**monepantelum**

monepantel


*N*-{2-cyano-1-[(2*S*)-5-cyano-2-(trifluoromethyl)phenoxy]propan-2-yl}-4-(trifluoromethylsulfanyl)benzamide

moné pantel

*N*-{[(1*S*)-1-cyano-2-[5-cyano-2-(trifluorométhy)]-1-méthylphénoxy]-4-[(trifluorométhy)]sulfanyl]benzamide

monepantel

*N*-{2-ciano-1-[(2*S*)-5-ciano-2-(trifluorometil)fenoxi]propan-2-il}-4-(trifluorometilsulfanil)benzamida

C<sub>20</sub>H<sub>13</sub>F<sub>6</sub>N<sub>3</sub>O<sub>2</sub>S**nelivaptanum**

nelivaptan


(2*S*,4*R*)-1-[(3*R*)-5-chloro-1-[(2,4-dimethoxybenzene)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1*H*-indol-3-yl]-4-hydroxy-*N,N*-dimethylpyrrolidine-2-carboxamide

nélivaptan

(2*S*,4*R*)-1-[(3*R*)-5-chloro-1-[(2,4-diméthoxyphényl)sulfonyl]-3-(2-méthoxyphényl)-2-oxo-2,3-dihydro-1*H*-indol-3-yl]-4-hydroxy-*N,N*-diméthylpyrrolidine-2-carboxamide

nelivaptán

(2*S*,4*R*)-1-[(3*R*)-5-cloro-1-[(2,4-dimetoxibenceno)sulfonyl]-3-(2-metoxifenil)-2-oxo-2,3-dihidro-1*H*-indol-3-il]-4-hidroxi-*N,N*-dimetilpirrolidina-2-carboxamida

C<sub>30</sub>H<sub>32</sub>ClN<sub>3</sub>O<sub>8</sub>S**nesbuvirum**

nesbuvir


5-cyclopropyl-2-(4-fluorophenyl)-6-[*N*-(2-hydroxyethyl)metanesulfonamido]-*N*-methyl-1-benzofuran-3-carboxamide

nesbuvir

5-cyclopropil-2-(4-fluorophényl)-6-[(2-hydroxyéthyl)(méthylsulfonyl)amino]-*N*-méthyl-1-benzofurane-3-carboxamide

nesbuvir

5-ciclopropil-2-(4-fluorofenil)-6-[*N*-(2-hidroxietyl)metanosulfonamido]-*N*-metil-1-benzofuran-3-carboxamida

C<sub>22</sub>H<sub>23</sub>FN<sub>2</sub>O<sub>5</sub>S

**odanacatibum**  
odanacatib


(2*S*)-*N*-(1-cyanocyclopropyl)-4-fluoro-4-méthyl-2-((1*S*)-2,2,2-trifluoro-1-(4'-(methanesulfonyl)-[1,1'-biphényl]-4-yl)éthyl)amino)=pentanamide

odanacatib

(2*S*)-*N*-(1-cyanocyclopropyl)-4-fluoro-4-méthyl-2-((1*S*)-2,2,2-trifluoro-1-(4'-(méthylsulfonyl)biphényl-4-yl)éthyl)amino)pentanamide

odanacatib

(2*S*)-*N*-(1-cianociclopropil)-4-fluoro-4-metil-2-((1*S*)-2,2,2-trifluoro-1-(4'-(metanosulfonyl)-[1,1'-bifenil]-4-il)etil)amino)pentanamida

C<sub>25</sub>H<sub>27</sub>F<sub>4</sub>N<sub>3</sub>O<sub>3</sub>S

**omacetaxini mepesuccinas**  
omacetaxine mepesuccinate


1-[(1*S*,3*aR*,14*bS*)-2-methoxy-1,5,6,8,9,14*b*-hexahydro-4*H*-cyclopenta[*a*][1,3]dioxolo[4,5-*h*]pyrrolo[2,1-*b*][3]benzazepin-1-yl]4-méthyl (2*R*)-2-hydroxy-2-(4-hydroxy-4-méthylpentyl)butanedioate

mépésuccinate d'omacétaxine

(2*R*)-2-hydroxy-2-(4-hydroxy-4-méthylpentyl)butanedioate de 1-[(1*S*,3*aR*,14*bS*)-2-méthoxy-1,5,6,8,9,14*b*-hexahydro-4*H*-cyclopenta[*a*][1,3]dioxolo[4,5-*h*]pyrrolo[2,1-*b*][3]benzazépin-1-yle] et de 4-méthyle

mepesuccinato de omacetaxina

(2*R*)-2-hidroxi-2-(4-hidroxi-4-metilpentil)butanodioato de 1-[(1*S*,3*aR*,14*bS*)-2-metoxi-1,5,6,8,9,14*b*-hexahidro-4*H*-ciclopenta[*a*][1,3]dioxolo[4,5-*h*]pirrolo[2,1-*b*][3]benzazepin-1-ilo] y de 4-metilo

C<sub>29</sub>H<sub>39</sub>NO<sub>9</sub>

otelixizumabum\*  
otelixizumab

immunoglobulin G1, anti-(human CD3E) humanized/chimeric monoclonal TRX4 (ChAglyCD3); humanized gamma1 heavy chain 299N>A [humanized VH (*Homo sapiens* FR/*Rattus sp.* CDR) (119 residues [8.8.12])- *Homo sapiens* IGHG1\*01, 180N>A (CH2 84.4)] (222-216')-disulfide with chimeric lambda light chain 111G>R [*Rattus sp.* V-LAMBDA (110 residues [8.3.9])-*Homo sapiens* IGLC2\*01, 1G>R (1.5)] ; (228-228'': 231-231'')-bisdisulfide dimer

otélixizumab

immunoglobuline G1, anti-(CD3E humain) anticorps monoclonal humanisé/chimérique TRX4 (ChAglyCD3); chaîne lourde gamma1 humanisée 299N>A [VH humanisé (*Homo sapiens* FR/*Rattus sp.* CDR) (119 résidus [8.8.12])- *Homo sapiens* IGHG1\*01, 180N>A (CH2 84.4) (222-216')-disulfure avec la chaîne lambda chimérique 111G>R [*Rattus sp.* V-LAMBDA (110 résidus [8.3.9])-*Homo sapiens* IGLC2\*01, 1G>R (1.5)] ; dimère (228-228'': 231-231'')-bisdisulfure

otelixizumab

immunoglobulina G1, anti-(CD3E humano) anticuerpo monoclonal humanizado/quimérico TRX4 (ChAglyCD3); cadena pesada gamma1 humanizada 299N>A [VH humanizada (*Homo sapiens* FR/*Rattus sp.* CDR) (119 residuos [8.8.12])- *Homo sapiens* IGHG1\*01, 180N>A (CH2 84.4) (222-216')-disulfuro con la cadena lambda quimérica 111G>R [*Rattus sp.* V-LAMBDA (110 residuos [8.3.9])-*Homo sapiens* IGLC2\*01, 1G>R (1.5)] ; dímero (228-228'': 231-231'')-bisdisulfuro

C<sub>6448</sub>H<sub>9954</sub>N<sub>1718</sub>O<sub>2016</sub>S<sub>42</sub>

Heavy chain / Chaîne lourde / Cadena pesada

EVQLLESGGG	LVQPGGSLRL	SCAASGFTFS	SFPMWVRQA	PGKLEWVST	50
ISTSGGRITY	RDSVKGRFTI	SRDNKNTLY	LQMNSLRAED	TAVYYCAKFR	100
QYSGGFDFYWG	QGTLVTVSSA	STKGPVFPFL	APSSKSTSGG	TAALGCLVKD	150
YFPEPVTVSW	NSGALTSGVH	TFFAVLQSSG	LYSLSSVTV	PSSSLGTQTY	200
ICNVNHPKSN	TKVDKKEPK	SCDKTHTCPP	CPAPPELLGPP	SVFLPFPKPK	250
DTLMISSRTP	VTCVVVDVSH	EDPEVKFNWY	VDGVEVHNAK	TKPREPQYAS	300
TYRIVSVLTV	LHQDWLNGKE	YKCKVSNKAL	PAPIEKTISK	AKGQPREPQV	350
YTLPPSRDEL	TKNQVSLTCL	VKGFYPSDIA	VEWESNGQPE	NNYKTTTPVL	400
DSDGSFFLYS	KLTVDKSRWQ	QGNVFSCSVM	HEALHNHYTQ	KSLSLSPGK	449

Light chain / Chaîne légère / Cadena ligera

DIQLTQPNV	STSLGTVKL	SCTLSGSGNIE	NNYVHWYQLY	EGRSPPTMIY	50'
DDDKRFDGVP	DRFSGSIDRS	SNSAFLTIHN	VAIEDEAIYF	CHSYVSSFNV	100'
FGGGKLTIVL	RQPKAAPSVT	LFPPSSSEELQ	ANKATLVCLI	SDFYPGAVTV	150'
AWKADSSPVK	AGVETTPFSK	QSNNKYAASS	YLSLTPEQWK	SHRYSYSCQVT	200'
HEGSTVEKTV	APTECS				216'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

22-96	22'-96''	22'-91'	22''-91'''	138-197'	138''-197'''	146-202	146''-202'''
215'-222	215''-222''	228-228''	231-231''	263-323'	263''-323'''	369-427	369''-427'''

**pegloticasum\***  
pegloticase



tetramer  $\alpha_4$  of des-(1-5)-[6-threonine,45-threonine,290-lysine,300-serine]uricase (EC 1.7.3.3, urate oxidase) from *Sus scrofa* (porcine), non acetylated, of which some of the lysine 6-amine residues are engaged in a carbamate linkage with a monomethyl ether of polyoxyethylene (macrogol)

## pégloticase

tétramère  $\alpha_4$  du des-(1-5)-[6-thrénine,45-thréonine,290-lysine,300-sérine]uricase (EC 1.7.3.3, urate oxydase) de *Sus scrofa* (porc) non acétylé dont certaines fonctions 6-amine de lysines sont engagées dans une liaison carbamate avec un éther monométhylé de polyoxyéthylène (macrogol)

## pegloticasa

tetrámero  $\alpha_4$  de la des-(1-5)-[6-treonina,45-treonina,290-lisina,300-serina]uricasa (EC 1.7.3.3, urato oxidasa) de *Sus scrofa* (porc) no acetilada algunas de cuyas funciones 6-amino de las lisinas forman uniones carbamato con un éter monometílico de polioxiétileno (macrogol)



H2N-R: Peptide monomer / Peptide monomère / Peptido monómero

TYKKN	DEVEFVRTGY	GKDMIKVLHI	QRDGKYHSIK	EVATTVQLTL	50
SSKKDYLHGD	NSDVIPTDTI	KNTVNVLAKF	KGIKSIETFA	VTICEHFLSS	100
FKHVIRAQVY	VEEVPWKRFE	KNGVKHVHAF	IYTPGTTHFC	EVEQIRNGPP	150
VIHSGIKDLK	VLKTTQSGFE	GFIKDQPTTL	PEVKDRCFAT	QVYCKWRVHQ	200
GRDVFPEATW	DTVRSIVLQK	FAGPYDKGEY	SPSVQKTLTD	IQVLTGLQVP	250
EIEDMEISLP	NIHYLNIDMS	KMGLINKKEEV	LLPLDNPYGK	ITGTVKRKLS	300
SRL					303

**preladenantum**  
preladenant



2-(furan-2-yl)-7-(2-{4-[4-(2-methoxyethoxy)phenyl]piperazin-1-yl}ethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine

## préladénant

2-(furan-2-yl)-7-(2-{4-[4-(2-méthoxyéthoxy)phényl]pipérazin-1-yl}éthyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine

## preladenant

2-(furan-2-il)-7-(2-{4-[4-(2-metoxietoxi)fenil]piperazin-1-il}etil)-7H-pirazolo[4,3-e][1,2,4]triazolo[1,5-c]pirimidin-5-amina



**radiprodilum**


radiprodil

2-{4-[(4-fluorophenyl)methyl]piperidin-1-yl}-2-oxo-*N*-(2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)acetamide

radiprodil

2-{4-[(4-fluorophényl)méthyl]pipéridin-1-yl}-2-oxo-*N*-(2-oxo-2,3-dihydrobenzoxazol-6-yl)acétamide

radiprodil

2-{4-[(4-fluorofenil)metil]piperidin-1-il}-2-oxo-*N*-(2-oxo-2,3-dihidro-1,3-benzoxazol-6-il)acetamidaC<sub>21</sub>H<sub>20</sub>FN<sub>3</sub>O<sub>4</sub>**remoglifozini etabonas**


remoglifozin etabonate

5-methyl-1-(propan-2-yl)-4-({4-[(propan-2-yl)oxy]phenyl)methyl}-1*H*-pyrazol-3-yl 6-*O*-(ethoxycarbonyl)-β-*D*-glucopyranoside

étabonate de rémoglifozine

6-*O*-(éthoxycarbonyl)-β-*D*-glucopyranoside de 5-méthyl-4-{{4-(1-méthyléthoxy)phényl}méthyl}-1-(1-méthyléthyl)-1*H*-pyrazol-3-yle

etabonato de remoglifozina

6-*O*-(etoxicarbonil)-β-*D*-glucopiranosido de 5-metil-1-(propan-2-il)-4-{{4-[(propan-2-il)oxil]fenil}metil}-1*H*-pirazol-3-iloC<sub>26</sub>H<sub>38</sub>N<sub>2</sub>O<sub>9</sub>**retosibanum**

retosiban

(3*R*,6*R*)-6-[(2*S*)-butan-2-yl]-3-(2,3-dihydro-1*H*-inden-2-yl)-1-[(1*R*)-1-(2-methyl-1,3-oxazol-4-yl)-2-(morpholin-4-yl)-2-oxoethyl]piperazine-2,5-dione


rétosiban

(3*R*,6*R*)-3-(2,3-dihydro-1*H*-indén-2-yl)-1-[(1*R*)-1-(2-méthylloxazol-4-yl)-2-(morpholin-4-yl)-2-oxoéthyl]-6-[(1*S*)-1-méthylpropyl]pépérazine-2,5-dione

retosibán

(3*R*,6*R*)-6-[(2*S*)-butan-2-il]-3-(2,3-dihidro-1*H*-inden-2-il)-1-[(1*R*)-1-(2-metil-1,3-oxazol-4-il)-2-(morfolin-4-il)-2-oxoetil]piperazina-2,5-diona



$C_{27}H_{34}N_4O_5$ **riociguatum**


riociguat

methyl *N*-(4,6-diamino-2-[(2-fluorophenyl)methyl]-1*H*-pyrazolo[3,4-*b*]pyridin-3-yl)pyrimidin-5-yl)-*N*-methylcarbamate

riociguat

(4,6-diamino-2-[(2-fluorophényl)méthyl]-1*H*-pyrazolo[3,4-*b*]pyridin-3-yl)pyrimidin-5-yl)méthylcarbamate de méthyle

riociguat

(4,6-diamino-2-[(2-fluorofenil)metil]-1*H*-pirazolo[3,4-*b*]piridin-3-il)pirimidin-5-il)metilcarbamato de metilo $C_{20}H_{19}FN_8O_2$ **rolofyllinum**


rolofylline

1,3-dipropyl-8-(tricyclo[3.3.1.0<sup>3,7</sup>]nonan-3-yl)-3,7-dihydro-1*H*-purin-2,6-dione

rolofylline

1,3-dipropyl-8-(tricyclo[3.3.1.0<sup>3,7</sup>]non-3-yl)-3,7-dihydro-1*H*-purine-2,6-dione

rolofyllina

1,3-dipropil-8-(triciclo[3.3.1.0<sup>3,7</sup>]nonan-3-il)-3,7-dihidro-1*H*-purina-2,6-diona $C_{20}H_{28}N_4O_2$ 

<b>tenatumomabum*</b> tenatumomab	immunoglobulin G2b, anti-[human tenascin C (TNC, hexabrachion, HBX) <i>Mus musculus</i> ] monoclonal antibody ST2146; gamma2b heavy chain ( <i>Mus musculus</i> VH [8.8.13]-IGHG2B*02 from clone ST2146) (135-219')-disulfide with kappa light chain ( <i>Mus musculus</i> V-KAPPA [11.3.9]-IGKC*01 from clone ST 2146); (229-229":232-232":235-235":238-238")-tetradisulfide dimer
ténatumomab	immunoglobuline G2b, anti-[tenascine C humaine (TNC, hexabrachion, HBX) <i>Mus musculus</i> ] anticorps monoclonal murin ST2146; chaîne lourde gamma2b ( <i>Mus musculus</i> VH [8.8.13]-IGHG2B*02 du clone ST2146) (135-219')-disulfure avec la chaîne légère kappa ( <i>Mus musculus</i> V-KAPPA [11.3.9]-IGKC*01 du clone ST 2146); dimère (229-229":232-232":235-235":238-238")-tétradisulfide
tenatumomab	immunoglobulina G2b, anti-[tenascina C humana (TNC, hexabrachion, HBX) <i>Mus musculus</i> ] anticuerpo monoclonal murino ST2146; cadena pesada gamma2b ( <i>Mus musculus</i> VH [8.8.13]-IGHG2B*02 del clon ST2146) (135-219')-disulfuro con la cadena ligera kappa ( <i>Mus musculus</i> V-KAPPA [11.3.9]-IGKC*01 del clon ST 2146); dímero (229-229":232-232":235-235":238-238")-tetradisulfuro

## Heavy chain / Chaîne lourde / Cadena pesada

```

EIQLQQSGPE LVKPGASVKV SCKASGYAFT SYNMYWVKQS HGKSLEWIGY 50
IDPYNGVTSY NQKFKGKATL TVDKSSSTAY MHLNLSLTSR SAVVYCARGG 100
GSIYYAMDYW GQGTSVTVSS AKITPPSVVYP LAPGCGDITG SSVTLGCLVK 150
GYFPESVTVT WNSGSLSSSV HTFPALLQSG LYTMSSSVTV PSSTWPSQTV 200
TCSVAHPASS TTVDKLEPS GPISITINPC PCKECKCPA PNLEGGPSVF 250
IFPPNIKDV L MISLTPKVT C VVVDVSEDDP DVQISWVFN VEVHTAQQT 300
HREDYNSTIR VVSTLPIQH Q DWMSGKEFK KVNNDLPS IERTISKIKG 350
LVRAPQVYIL PPPAEQLSRK DVSLTCLVVG FNPGLSV E VTSNGHTEENY 400
KDTAPVLDSD GSYFIYSKLN MKTSKWEKTD SFSCNVRHEG LKNYYLKKTI 450
SRSPGK 456

```

## Light chain / Chaîne légère / Cadena ligera

```

DIVMTQAAPS VPVTPGESVS ISCRSSKSL L HSGNNTYLYW FLQRPGQSPQ 50
LLIYRMSNLA SGVPDRFSGS GSGTAFTLRI SRVEAEDVGV YYCMQHLEYP 100
LTFGAGTKLE LKRADAAPT V SIFPPSSEQL TSGGASV VCF LNNFYPKDIN 150
VKWKIDGSER QNGVLNSWTD QDSKDSTYSM SSTLTLTKDE YERHNSYTCE 200
ATHKTSTSPI VKSFNRNEC 219

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
 Bold and underlined **Cysteins** are those involved in disulphide bridges.

<b>tertomotidum</b> tertomotide	human telomerase reverse transcriptase (EC 2.7.7.49)-(611-626)-peptide (telomerase catalytic subunit fragment)
tertomotide	téломérase transcriptase réverse humaine (EC 2.7.7.49)-(611-626)-peptide (fragment de la sous-unité catalytique de la téломérase)
tertomotida	transcriptasa inversa humana telomerasa (EC 2.7.7.49)-(611-626)-péptido (fragmento de la subunidad catalítica de la telomerasa)

 $C_{85}H_{146}N_{26}O_{21}$ 

H—Glu—Ala—Arg—Pro—Ala—Leu—Leu—Thr—Ser—

Arg—Leu—Arg—Phe—Ile—Pro—Lys—OH

10

16

<b>tigatuzumabum*</b> tigatuzumab	immunoglobulin G1, anti-[ <i>Homo sapiens</i> TNFRSF10B (tumor necrosis factor receptor superfamily member 10b, DR5, TRAIL-R2, CD262)] humanized monoclonal TRA-8 (or CS-1008); gamma1 heavy chain [humanized VH ( <i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR) [8.8.12] - <i>Homo sapiens</i> IGHG1*03] (222-213')-disulfide with kappa light chain [humanized V-KAPPA ( <i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR) [6.3.8] - <i>Homo sapiens</i> IGKC*01]; (228-228":231-231")-bisdisulfide dimer																																																																																				
tigatuzumab	mmunoglobuline G1, anti-[ <i>Homo sapiens</i> TNFRSF10B (membre 10b de la superfamille des récepteurs du facteur de nécrose tumorale, DR5, TRAIL-R2, CD262)] anticorps monoclonal humanisé TRA-8 (ou CS-1008); chaîne lourde gamma1 [VH humanisé ( <i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR) [8.8.12] - <i>Homo sapiens</i> IGHG1*03] (222-213')-disulfure avec la chaîne légère kappa [V-KAPPA humanisé ( <i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR) [6.3.8] - <i>Homo sapiens</i> IGKC*01]; dimère (228-228":231-231")-bisdisulfure																																																																																				
tigatuzumab	immunoglobulina G1, anti-[ <i>Homo sapiens</i> TNFRSF10B (miembro 10b de la superfamilia de receptores del factor de necrosis tumoral, DR5, TRAIL-R2, CD262)] anticuerpo monoclonal humanizado TRA-8 (o CS-1008); cadena pesada gamma1 [VH humanizada ( <i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR) [8.8.12] - <i>Homo sapiens</i> IGHG1*03] (222-213')-disulfuro con la cadena ligera kappa [V-KAPPA humanizada ( <i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR) [6.3.8] - <i>Homo sapiens</i> IGKC*01]; dímero (228-228":231-231")-bisdisulfuro																																																																																				
	<p>C<sub>6406</sub>H<sub>9924</sub>N<sub>1716</sub>O<sub>2012</sub>S<sub>46</sub></p> <p>Heavy chain / Chaîne lourde / Cadena pesada</p> <table border="0"> <tr><td>EVQLVESGGG</td><td>LVQPFGSLRL</td><td>SCAASGFTFS</td><td>SYVMSWVRQA</td><td>PGKGLEWVAT</td><td>50</td></tr> <tr><td>ISSGGSYTY</td><td>PDSVKGRFTI</td><td>SRDNAKNTLY</td><td>LQMNSLRAED</td><td>TAVYICARRG</td><td>100</td></tr> <tr><td>DSMITTDYWG</td><td>QGTLLVTVSSA</td><td>STKGPSVFPPL</td><td>APSSKSTSGG</td><td>TAALGCLVKD</td><td>150</td></tr> <tr><td>YFPEPTVYSW</td><td>NSGALTSGVH</td><td>TFPVAVLQSSG</td><td>LYSLSSVVTV</td><td>PSSSLGQTQY</td><td>200</td></tr> <tr><td>ICNVNHKPSN</td><td>TKVDKRVKPK</td><td>SCDKTHTCPP</td><td>CPAPPELLGGP</td><td>SVFLFPPKPK</td><td>250</td></tr> <tr><td>DTLMI SRTPE</td><td>VTCVVVDVSH</td><td>EDPEVKFNWY</td><td>VDGVEVHNAK</td><td>TKPREQYNS</td><td>300</td></tr> <tr><td>TYR VVSVLTV</td><td>LHQDNLNGKE</td><td>YKCKVSNKAL</td><td>PAPIEKTI SK</td><td>AKGQPREPQV</td><td>350</td></tr> <tr><td>YTLPPSRREM</td><td>TKNQVSLTCL</td><td>VKGFPYSDIA</td><td>VEWESNGQPE</td><td>NNYKTTTPPV</td><td>400</td></tr> <tr><td>DSGSEFFLYS</td><td>KLTVDKSRWQ</td><td>QGNVVFSCSVM</td><td>HEALHNHYTQ</td><td>KSLSLSPGK</td><td>449</td></tr> </table> <p>Light chain / Chaîne légère / Cadena ligera</p> <table border="0"> <tr><td>DIQMTQSPSS</td><td>LSASVGRVVT</td><td>ITCKASQDVG</td><td>TAVAWYQQKP</td><td>GKAPKLLIYW</td><td>50'</td></tr> <tr><td>ASTRHTGVP</td><td>RFSGSGSGTD</td><td>FTLTISLQP</td><td>EDFATYYCQQ</td><td>YSSYRTFGQG</td><td>100'</td></tr> <tr><td>TKVEIKRTVA</td><td>APSVFIFPPS</td><td>DEQLKSGTAS</td><td>VVCLLNNFYP</td><td>REAKVQWKVD</td><td>150'</td></tr> <tr><td>NALQSGNSQE</td><td>SVTEQDSKDS</td><td>TYSLSSITLTL</td><td>SKADYEKHKV</td><td>YACEVTHQGL</td><td>200'</td></tr> <tr><td>SSPVTKSFNR</td><td>GEC</td><td>213'</td><td></td><td></td><td></td></tr> </table> <p>Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  22-96 22"-96" 23"-88" 23"-88" 133'-193" 133"-193" 146-202 146"-202"  213'-222 213"-222" 228-228" 231-231" 263-323 263"-323" 369-427 369"-427"</p>	EVQLVESGGG	LVQPFGSLRL	SCAASGFTFS	SYVMSWVRQA	PGKGLEWVAT	50	ISSGGSYTY	PDSVKGRFTI	SRDNAKNTLY	LQMNSLRAED	TAVYICARRG	100	DSMITTDYWG	QGTLLVTVSSA	STKGPSVFPPL	APSSKSTSGG	TAALGCLVKD	150	YFPEPTVYSW	NSGALTSGVH	TFPVAVLQSSG	LYSLSSVVTV	PSSSLGQTQY	200	ICNVNHKPSN	TKVDKRVKPK	SCDKTHTCPP	CPAPPELLGGP	SVFLFPPKPK	250	DTLMI SRTPE	VTCVVVDVSH	EDPEVKFNWY	VDGVEVHNAK	TKPREQYNS	300	TYR VVSVLTV	LHQDNLNGKE	YKCKVSNKAL	PAPIEKTI SK	AKGQPREPQV	350	YTLPPSRREM	TKNQVSLTCL	VKGFPYSDIA	VEWESNGQPE	NNYKTTTPPV	400	DSGSEFFLYS	KLTVDKSRWQ	QGNVVFSCSVM	HEALHNHYTQ	KSLSLSPGK	449	DIQMTQSPSS	LSASVGRVVT	ITCKASQDVG	TAVAWYQQKP	GKAPKLLIYW	50'	ASTRHTGVP	RFSGSGSGTD	FTLTISLQP	EDFATYYCQQ	YSSYRTFGQG	100'	TKVEIKRTVA	APSVFIFPPS	DEQLKSGTAS	VVCLLNNFYP	REAKVQWKVD	150'	NALQSGNSQE	SVTEQDSKDS	TYSLSSITLTL	SKADYEKHKV	YACEVTHQGL	200'	SSPVTKSFNR	GEC	213'			
EVQLVESGGG	LVQPFGSLRL	SCAASGFTFS	SYVMSWVRQA	PGKGLEWVAT	50																																																																																
ISSGGSYTY	PDSVKGRFTI	SRDNAKNTLY	LQMNSLRAED	TAVYICARRG	100																																																																																
DSMITTDYWG	QGTLLVTVSSA	STKGPSVFPPL	APSSKSTSGG	TAALGCLVKD	150																																																																																
YFPEPTVYSW	NSGALTSGVH	TFPVAVLQSSG	LYSLSSVVTV	PSSSLGQTQY	200																																																																																
ICNVNHKPSN	TKVDKRVKPK	SCDKTHTCPP	CPAPPELLGGP	SVFLFPPKPK	250																																																																																
DTLMI SRTPE	VTCVVVDVSH	EDPEVKFNWY	VDGVEVHNAK	TKPREQYNS	300																																																																																
TYR VVSVLTV	LHQDNLNGKE	YKCKVSNKAL	PAPIEKTI SK	AKGQPREPQV	350																																																																																
YTLPPSRREM	TKNQVSLTCL	VKGFPYSDIA	VEWESNGQPE	NNYKTTTPPV	400																																																																																
DSGSEFFLYS	KLTVDKSRWQ	QGNVVFSCSVM	HEALHNHYTQ	KSLSLSPGK	449																																																																																
DIQMTQSPSS	LSASVGRVVT	ITCKASQDVG	TAVAWYQQKP	GKAPKLLIYW	50'																																																																																
ASTRHTGVP	RFSGSGSGTD	FTLTISLQP	EDFATYYCQQ	YSSYRTFGQG	100'																																																																																
TKVEIKRTVA	APSVFIFPPS	DEQLKSGTAS	VVCLLNNFYP	REAKVQWKVD	150'																																																																																
NALQSGNSQE	SVTEQDSKDS	TYSLSSITLTL	SKADYEKHKV	YACEVTHQGL	200'																																																																																
SSPVTKSFNR	GEC	213'																																																																																			
<b>velaglycerasum alfa*</b> velaglycerase alfa	human glucosylceramidase (EC 3.2.1.45 or beta-glucocerebrosidase), glycoform $\alpha$																																																																																				
vélagucérase alfa	glucosylcéramidase humaine (EC 3.2.1.45 ou bêta-glucocérébrosidase), glycoform $\alpha$																																																																																				
velaglycerasa alfa	glucosilceramidasa humana (EC 3.2.1.45 o beta-glucocerebrosidasa), glicofoma $\alpha$																																																																																				

C<sub>2532</sub>H<sub>3850</sub>N<sub>672</sub>O<sub>711</sub>S<sub>16</sub>

ARPCIPKSPFG	YSSVVCVCNA	TYCDSFDPPT	FPALGTFRSY	ESTRSGRRME	50
LSMGPIQANH	TGTGLLLTLQ	PEQKFQKVKG	FGGAMTDAAA	LNILALSPPA	100
QNLLKSYFS	EEGIGYNIIR	VPMASCDFSI	RTYTYADTFD	DFQLHNSFLP	150
EEDTKLKIPL	IHRALQLAQR	FVSLLASPWT	SFTWLKTNGA	VNGKGSLLKQ	200
PGDIYHQIWA	RYFVKFLDAY	AEHKLQFWAV	TAENEPSAGL	LSGYFPQCLG	250
FTPEHQDFI	ARDLGFPTLAN	STHHNVRLLM	LDDQRLLLPH	WAKVVLTDFE	300
AAKYVHGIAV	HWYLDPLAPA	KATLGETHRL	FPNTMLFASE	ACVGSKFWEQ	350
SVRLGSWDRG	MQYSHSIIITN	LLYHVVGWTD	WNLALNPEGG	PNWVRFVDS	400
PIIVDITKDT	FYKQPMFYHL	GHSKFIPEG	SQRVGLVASQ	KNDLDAVALM	450
HPDGSVVVVV	LNRSSKDVPL	TIKDPVAVGFL	ETISPGYSIH	TYLWRRQ	497

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
4-16 18-23

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación  
Asn-19 Asn-59 Asn-146 Asn-270 Asn-462

## veltuzumabum\*

veltuzumab

immunoglobulin G1, anti-[*Homo sapiens* CD20 (MS4A1, membrane-spanning 4-domains subfamily A member 1, B lymphocyte surface antigen B1, Leu-16, Bp35)] humanized monoclonal IMMU-106 (or hA20); gamma1 heavy chain [humanized VH (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.14] -*Homo sapiens* IGHG1\*03] (224-213')-disulfide with kappa light chain [humanized V-KAPPA (*Homo sapiens* FR/*Mus musculus* CDR) [5.3.9] -*Homo sapiens* IGKC\*01]; (230-230":233-233")-bisdisulfide dimer

veltuzumab

immunoglobuline G1, anti-[*Homo sapiens* CD20 (MS4A1, membre 1 de la sous-famille A à 4 domaines transmembranaires, antigène de surface B1 des lymphocytes B, Leu-16, Bp35)] anticorps monoclonal humanisé IMMU-106 (ou hA20); chaîne lourde gamma1 [VH humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.14] - *Homo sapiens* IGHG1\*03] (224-213')-disulfure avec la chaîne légère kappa [V-KAPPA humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [5.3.9] -*Homo sapiens* IGKC\*01]; dimère (230-230":233-233")-bisdisulfure

veltuzumab

inmunoglobulina G1, anti-[*Homo sapiens* CD20 (MS4A1, miembro 1 de la subfamilia A con 4 dominios transmembranarios, antígeno de superficie B1 de los linfocitos B, Leu-16, Bp35)] anticuerpo monoclonal humanizado IMMU-106 (ou hA20); cadena pesada gamma1 [VH humanizado (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.14] - *Homo sapiens* IGHG1\*03] (224-213')-disulfuro con la cadena ligera kappa [V-KAPPA humanizado (*Homo sapiens* FR/*Mus musculus* CDR) [5.3.9] -*Homo sapiens* IGKC\*01]; dímero (230-230":233-233")-bisdisulfuro

C<sub>6458</sub>H<sub>9918</sub>N<sub>1706</sub>O<sub>2026</sub>S<sub>46</sub>

Heavy chain / Chaîne lourde / Cadena pesada					
QVQLQQSGAE	VKKPGSSVKV	SCKASGYTFT	SYNMHWVKA	PGQGLEWIGA	50
IYPGMGDTSY	NQKFKGKATL	TADESTNTAY	MELSSLRSED	TAFYICARST	100
YVGGDWYFDV	WQQGTTVTIS	SASTKGPSVF	PLAPSSKSTS	GGTAALGCLV	150
KDYFPEPVTV	SWNSGALTSV	VHTFPAVLQS	SGLYSLSSVV	TVPSSSLGTQ	200
TYICNVNHKP	SNTKVDRKVE	PKSCDKTHTC	PPCPAPPELLG	GPSVFLFPPK	250
PKDTLMISRT	PEVTCVVVDV	SHEDPEVKFN	WYVDGVEVHN	AKTKPREEQY	300
NSTYRVVSVL	TVLHQDWLNG	KEYKCKVSNK	ALPAPIEKTI	SKAKGQPREP	350
QVYTLPPSRE	EMTKNQVSLT	CLVKGFYPSD	IAVEVESNGQ	FENNYKTPPP	400
VLDSGDSFPL	YSKLTVDKSR	WQQGNVFCSS	VMHEALHNYH	TQKSLSLSPG	450
K					451
Light chain / Chaîne légère / Cadena ligera					
DIQLTQSPSS	LSASVGDRTV	MTCRASSSVS	YIHWFOQKPG	KAPKPIWIAT	50
SNLASCYFVR	FSGSGSGTDY	TFTISSLQPE	DIATYTCQQW	TSNPDPTFGG	100
TKLEIKRTVA	APSVFIPFPPS	DEQLKSGTAS	VVCLLNRFYP	REAKVQWKVD	150
NALQSGNSQE	SVTEQDSKDS	TYSLSSTLTL	SKADYEKHKV	YACEVTHQGL	200
SSPVTKSFNR	GEC				213

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
22-96 22'-96" 23'-87" 23"-87" 133'-193" 133"-193" 148-204 148"-204"  
213'-224 213"-224" 230-230" 233-233" 265-325 265"-325" 371-429 371"-429"

**viquidacinum**

viquidacin


(3*R*,4*R*)-4-[(3*S*)-3-[3-fluoro-6-methoxyquinolin-4-yl]-3-hydroxypropyl]-1-[2-[(thiophen-2-yl)sulfanyl]ethyl]piperidine-3-carboxylic acid

viquidacine

acide (3*R*,4*R*)-4-[(3*S*)-3-(3-fluoro-6-méthoxyquinoléin-4-yl)-3-hydroxypropyl]-1-[2-(thiophén-2-ylsulfanyl)éthyl]pipéridine-3-carboxylique

viquidacina

ácido (3*R*,4*R*)-4-[(3*S*)-3-[3-fluoro-6-metoxiquinolin-4-il]-3-hidroxiopropil]-1-[2-[(tiofen-2-il)sulfanil]etil]piperidina-3-carboxílico

 $C_{25}H_{29}FN_2O_4S_2$ 

---

**AMENDMENTS TO PREVIOUS LISTS  
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES  
MODIFICACIONES A LAS LISTAS ANTERIORES**

**Recommended International Nonproprietary Names (Rec. INN): List 59**  
**Dénominations communes internationales recommandées (DCI Rec.): Liste 59**  
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 59**  
**(WHO Drug Information, Vol. 22, No. 1, 2008)**

p. 43	<i>suprimáse</i> albinterferón alfa-2b	<i>insertése</i> albinterferón alfa-2b
p. 48	<i>supprimer</i> céftaroline fosamil	<i>insérer</i> ceftaroline fosamil

- \* Electronic structure available on Mednet: <http://mednet.who.int/>
- \* Structure électronique disponible sur Mednet: <http://mednet.who.int/>
- \* Estructura electrónica disponible en Mednet: <http://mednet.who.int/>

**Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales**

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.